-
Chinese (Simplified)
-
English
-
German
-
Korean
-
Spanish
Chinese (Simplified)
English
German
Korean
Spanish
Sign up for an account to enjoy easy online shopping and instant order tracking.
Introducing the Recombinant Human Parkinson Disease Protein 7 (PARK7), a vital tool for advancing your cancer research endeavors. PARK7, a multifunctional protein, is implicated in various cellular processes, including oxidative stress response, cell proliferation, and apoptosis. Its dysregulation has been linked to several cancer types and neurodegenerative diseases, such as Parkinson's disease. Our Recombinant Human PARK7 protein is expressed in E. coli, ensuring high levels of stability and bioactivity. The protein encompasses a partial sequence (1-174aa) and features an N-terminal 6xHis-SUMO tag for efficient purification and detection. With a purity of greater than 90% as determined by SDS-PAGE, our PARK7 protein offers consistent performance across a wide range of experimental applications. Choose between liquid or lyophilized powder forms to suit your laboratory needs, and trust in our precision-engineered Recombinant Human PARK7 protein to provide reliable results for your cancer research.
Introducing the Recombinant Human Parkinson Disease Protein 7 (PARK7), a vital tool for advancing your cancer research endeavors. PARK7, a multifunctional protein, is implicated in various cellular processes, including oxidative stress response, cell proliferation, and apoptosis. Its dysregulation has been linked to several cancer types and neurodegenerative diseases, such as Parkinson’s disease.
Our Recombinant Human PARK7 protein is expressed in E. coli, ensuring high levels of stability and bioactivity. The protein encompasses a partial sequence (1-174aa) and features an N-terminal 6xHis-SUMO tag for efficient purification and detection. With a purity of greater than 90% as determined by SDS-PAGE, our PARK7 protein offers consistent performance across a wide range of experimental applications. Choose between liquid or lyophilized powder forms to suit your laboratory needs, and trust in our precision-engineered Recombinant Human PARK7 protein to provide reliable results for your cancer research.
| Cat.No | ACP03781 | Target Name | PARK7 |
|---|---|---|---|
| Target Synonyms | early onset) 7; Parkinson disease protein 7; Parkinson protein 7; Protein DJ-1; SP22 | Form | Liquid or Lyophilized powder |
| Expression System | E.coli | Expression Range | 1-174aa |
| Mol Weight | 34.3kDa | Protein Length | Partial |
| Purity | Greater than 90% as determined by SDS-PAGE. | Storage Buffer | 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0. |
| Target Species | Human | Uniprot ID | Q99497 |
|---|
Uniprot Id
Q99497
Target Species
Human
Target Name
PARK7
Target Full Name
Parkinson disease protein 7
Target Function
Multifunctional protein with controversial molecular function which plays an important role in cell protection against oxidative stress and cell death acting as oxidative stress sensor and redox-sensitive chaperone and protease. It is involved in neuroprotective mechanisms like the stabilization of NFE2L2 and PINK1 proteins, male fertility as a positive regulator of androgen signaling pathway as well as cell growth and transformation through, for instance, the modulation of NF-kappa-B signaling pathway. Has been described as a protein and nucleotide deglycase that catalyzes the deglycation of the Maillard adducts formed between amino groups of proteins or nucleotides and reactive carbonyl groups of glyoxals. But this function is rebuted by other works. As a protein deglycase, repairs methylglyoxal- and glyoxal-glycated proteins, and releases repaired proteins and lactate or glycolate, respectively. Deglycates cysteine, arginine and lysine residues in proteins, and thus reactivates these proteins by reversing glycation by glyoxals. Acts on early glycation intermediates (hemithioacetals and aminocarbinols), preventing the formation of advanced glycation endproducts (AGE) that cause irreversible damage. Also functions as a nucleotide deglycase able to repair glycated guanine in the free nucleotide pool (GTP, GDP, GMP, dGTP) and in DNA and RNA. Is thus involved in a major nucleotide repair system named guanine glycation repair (GG repair), dedicated to reversing methylglyoxal and glyoxal damage via nucleotide sanitization and direct nucleic acid repair. Protects histones from adduction by methylglyoxal, controls the levels of methylglyoxal-derived argininine modifications on chromatin. Able to remove the glycations and restore histone 3, histone glycation disrupts both local and global chromatin architecture by altering histone-DNA interactions as well as histone acetylation and ubiquitination levels. Displays a very low glyoxalase activity that may reflect its deglycase activity. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. Required for correct mitochondrial morphology and function as well as for autophagy of dysfunctional mitochondria. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Regulates astrocyte inflammatory responses, may modulate lipid rafts-dependent endocytosis in astrocytes and neuronal cells. In pancreatic islets, involved in the maintenance of mitochondrial reactive oxygen species (ROS) levels and glucose homeostasis in an age- and diet dependent manner. Protects pancreatic beta cells from cell death induced by inflammatory and cytotoxic setting. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Metal-binding protein able to bind copper as well as toxic mercury ions, enhances the cell protection mechanism against induced metal toxicity. In macrophages, interacts with the NADPH oxidase subunit NCF1 to direct NADPH oxidase-dependent ROS production, and protects against sepsis.
Target Involvement
Parkinson disease 7 (PARK7)
Target Subcellular Location
Cell membrane; Lipid-anchor. Cytoplasm. Nucleus. Membrane raft. Mitochondrion. Endoplasmic reticulum.
Target Protein Families
Peptidase C56 family
Target Tissue Specificity
Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain (at protein level). Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Expressed by panc
Target Research Area
Apoptosis, Cancer
Target Synonyms
CAP1; DJ-1; DJ1; DJ1 protein ; Epididymis secretory sperm binding protein Li 67p; FLJ27376; FLJ34360; FLJ92274; HEL S 67p; Oncogene DJ1; OTTHUMP00000001348; OTTHUMP00000001349; OTTHUMP00000001350; OTTHUMP00000001351; PARK7; PARK7_HUMAN; Parkinson disease (autosomal recessive, early onset) 7; Parkinson disease protein 7; Parkinson protein 7; Protein DJ-1; SP22
Target Background
The product of this gene belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. Defects in this gene are the cause of autosomal recessive early-onset Parkinson disease 7. Two transcript variants encoding the same protein have been identified for this gene.
Notification